Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Maze Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Maze Therapeutics's regulatory disclosures and financial reporting.
Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein reported an exercise-and-sell transaction in Common Stock. On May 14, 2026, he exercised stock options to acquire 15,000 shares at $10.42 per share, then sold the same 15,000 shares in open-market transactions at a weighted average price of $26.2236 per share, with individual sale prices ranging from $25.77 to $26.44. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After the sale, he reported holding no Common Stock directly, while retaining 222,407 stock options with a $10.42 exercise price expiring on October 26, 2032.
MAZE submitted a Rule 144 notice reporting proposed sales of Common shares, listing specific lots and dates. The filing lists numeric entries including 34502, 895,326.90, 55,345,261 and lot counts 2,594 and 31,908, and includes an expiration or related date of 05/15/2026.
The notice identifies transfers described as Gift with a named transferee, Jason Coloma, and references brokerage placement at UBS Financial Services Inc. on Eleven Madison Avenue. The filing appears to be an administrative Rule 144 disclosure of resale activity rather than a primary offering.
Janus Henderson Group plc reports beneficial ownership of 2,858,876 shares of Maze Therapeutics, Inc. common stock, representing 5.8% of the class as of 03/31/2026. The filing states the holdings are held across Janus Henderson–managed portfolios, with shared voting and dispositive power of 2,858,876 shares and no sole voting or dispositive power. The filing notes the Asset Managers exercise voting discretion for client accounts and disclaim rights to dividends or sale proceeds tied to those accounts. The signature on the amendment is dated 5/15/2026.
Maze Therapeutics, Inc. reported a Q1 2026 net loss of $24.2 million, narrower than the $32.8 million loss a year earlier, as it recorded $20.0 million of license revenue from a Shionogi milestone. Operating expenses rose to $46.6 million, driven by higher research and development and general and administrative costs.
The company ended March 31, 2026 with $362.9 million in cash, cash equivalents and marketable securities and had an accumulated deficit of $513.8 million. In February 2026 it put in place a $200.0 million at-the-market equity program and a Hercules term loan facility of up to $200.0 million, funding an initial $40.0 million tranche.
Maze is advancing two wholly owned clinical programs. MZE829, an APOL1 inhibitor for APOL1-mediated kidney disease, delivered positive Phase 2 proof-of-concept data and is being prepared for pivotal development. MZE782 showed favorable Phase 1 results, with Phase 2 trials in phenylketonuria and chronic kidney disease planned for 2026.
Maze Therapeutics reported first quarter 2026 results alongside important clinical and financing updates. The company generated $20.0 million in license revenue from a milestone tied to its MZE001 partnership, while R&D and G&A expenses rose to $34.1 million and $12.4 million, respectively.
Net loss narrowed to $24.2 million, or $0.45 per share, from $32.8 million, or $1.15 per share, a year earlier. Cash, cash equivalents and marketable securities were $362.9 million as of March 31, 2026, and the company highlighted a strong balance sheet of $528 million including April financing and milestone proceeds, supporting an expected cash runway into 2029.
Clinically, Maze reported positive topline Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease, showing meaningful reductions in proteinuria and no serious treatment-related adverse events, and it plans a pivotal trial in moderate AMKD without diabetes. Phase 2 proof-of-concept trials for MZE782 in PKU and CKD are planned to initiate in 2026.
Maze Therapeutics, Inc. is filing a post-effective amendment that converts its Prior Registration Statement into a Form S-3 and keeps on registration for resale up to 9,231,092 shares of common stock. The registered shares consist of 4,000,002 Initial Shares and up to 5,231,090 Warrant Shares issuable upon exercise of pre-funded warrants. The registration relates solely to resale by the identified selling stockholders; Maze will not receive proceeds from sales under this prospectus. The prospectus states the Selling Stockholders may sell the Shares at any time, at market or negotiated prices, through underwriters, brokers or private transactions, and will bear underwriting fees and transfer taxes. The company disclosed a last reported sale price of $25.52 per share as of May 11, 2026.
Maze Therapeutics, Inc. Chief Business and Strategy Officer Atul Dandekar exercised stock options to acquire a total of 14,305 shares of Common Stock on May 4, 2026. The options were exercised at an exercise price of $10.42 per share.
Following these transactions, Dandekar directly holds 24,808 shares of Common Stock. The exercised options relate to awards that vest monthly over 48 months, with one award noted as having become fully vested on February 1, 2026, subject to continued service conditions described in the award agreements.
Maze Therapeutics, Inc. director Charles J. Homcy reported a bona fide gift transfer of 7,422 shares of common stock on May 4, 2026. The gift was made for no consideration and is described as exempt under Rule 16b-5. After the transaction, Homcy directly holds 31,113 shares of Maze Therapeutics common stock, a total that includes shares previously held by the Charles J. Homcy Revocable Trust UA 11/4/1998.
Maze Therapeutics, Inc. chief business officer Atul Dandekar exercised stock options for 7,500 shares of common stock at $10.42 per share and on the same day sold 7,500 shares in an open-market transaction at a weighted average price of $25.3732 per share. Following these transactions, he directly holds 10,503 shares of Maze common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating the timing was set in advance rather than decided opportunistically.